Intravitreal therapy—success stories and challenges
Wiener Medizinische Wochenschrift · 2025
DOI: 10.1007/s10354-024-01070-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Wiener Medizinische Wochenschrift, 2025. Verfasst von Daniel Egger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria. daniel.egger@mistelbach.lknoe.at. Hauptthemen laut MEDLINE: Intravitreal Injections, Angiogenesis Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Paracelsus Medical University.
Abstract (Originalsprache)
Intravitreal injections have revolutionized the treatment of various sight-threatening diseases of the posterior segment of the eye. Initially explored for treatment of bacterial endophthalmitis, intravitreal injections rapidly expanded to combat retinal vascular disease in particular. Especially anti-vascular endothelial growth factor agents have emerged as a cornerstone of intravitreal therapy, targeting neovascular age-related macular degeneration and diabetic macular edema as important examples. Advances continue, with novel therapies such as complement inhibitors now available as treatment for geographic atrophy secondary to non-neovascular age-related macular degeneration, offering hope for a previously untreatable condition. Pioneering approaches such as the port delivery system and intravitreal gene therapy aim to improve treatment efficacy while minimizing patient burden. Despite notable successes, challenges for intravitreal therapies persist, including ocular and systemic complications and high treatment burden. Future research endeavors aim to address these challenges and enhance treatment outcomes. This comprehensive review critically evaluates the efficacy, safety, and cost-effectiveness of intravitreal injections, delving into emerging trends and future directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria. daniel.egger@mistelbach.lknoe.at.
- Karl Landsteiner University of Health Sciences, Krems, Austria. daniel.egger@mistelbach.lknoe.at.
- Paracelsus Medical University Salzburg, Salzburg, Austria. daniel.egger@mistelbach.lknoe.at.
- Department of Ophthalmology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.
- Karl Landsteiner University of Health Sciences, Krems, Austria.
- Department of Ophthalmology, Kepler University Clinic, Linz, Austria.
Förderung
- Paracelsus Medical University
Zitieren
APA
Egger, D., Heger, K. A., Bolz, M., Brinkmann, M. P., Krepler, K., Vecsei-Marlovits, P. V., Wedrich, A., & Waldstein, S. M. (2025). Intravitreal therapy—success stories and challenges. Wiener Medizinische Wochenschrift. https://doi.org/10.1007/s10354-024-01070-8
Vancouver
Egger D, Heger KA, Bolz M, Brinkmann MP, Krepler K, Vecsei-Marlovits PV, et al. Intravitreal therapy—success stories and challenges. Wiener Medizinische Wochenschrift. 2025. doi:10.1007/s10354-024-01070-8
BibTeX
@article{Egger2025,
author = {Egger, Daniel and Heger, Katharina A and Bolz, Matthias and Brinkmann, Max P and Krepler, Katharina and Vecsei-Marlovits, Pia Veronika and Wedrich, Andreas and Waldstein, Sebastian M},
title = {Intravitreal therapy—success stories and challenges},
journal = {Wiener Medizinische Wochenschrift},
year = {2025},
doi = {10.1007/s10354-024-01070-8}
}
EUVIMED